Advances in Modern Diabetes Management -- Tailored to Patient Needs

Despite significant scientific and clinical progress in the understanding and management of T2DM, patient care remains challenging. The approval of novel treatment options with improved safety, tolerability, and efficacy profiles (eg, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors) has expanded the therapeutic armamentarium for T2DM care. With this expanding array of agents, and the introduction of additional fixed-dose combinations, comes substantial challenges for physicians in selecting the most appropriate individualized regimen for their patients with T2DM.

The Challenging Type 2 Diabetes Mellitus Patient in Clinical Practice
Join Dr Raz for a case-based discussion on the management of patients with complicated and uncontrolled type 2 diabetes mellitus.

March 25, 2016
Recently Diagnosed Type 2 Diabetes: What to Do When Metformin Isn't Enough
Join Dr Bain for a case-based discussion on the management of overweight and obese patients with type 2 diabetes who fail metformin.

February 17, 2016
Managing Type 2 Diabetes: When to Intensify Therapy
Join Dr Montanya for a case-based discussion on the management of patients with type 2 diabetes in whom metformin fails.

February 17, 2016
Managing Type 2 Diabetes: Optimizing Therapy in the Obese
Join Dr Matthaei for a case-based discussion on difficult to manage type 2 diabetes in patients with obesity.

February 17, 2016
Novel Diabetes Therapies in Review -- Focus on DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
Join Drs Mehta, Nauck, and Charbonnel for a discussion on incorporating novel antihyperglycemic agents in the treatment of patients with T2DM.

January 27, 2016
Diabetes Care: Latest Data & Implications for Practice
Join Drs Cooper, Holst, Seufert, Vora, and Vilsbøll for a review of CV outcomes trials in type 2 diabetes.

December 15, 2015

Modern T2D TV: New and Emerging Treatments
This series will review recent data and provide insight on the use of new and emerging treatments for patients with type 2 diabetes (T2D).

In Memory of Professor Stephan Matthaei

With great sadness Medscape Education has learnt of the sudden and unexpected death of Professor Stephan Matthaei in early April 2016. Prof Matthaei was an internationally respected diabetologist, the former President and Board member of the German Diabetes Association and the Head of the Diabetes-Zentrum Quakenbrück in Germany. Prof. Matthaei was a member of the Steering Committee for this Advances in Diabetes Management, and was a regular contributor to educational programs on Medscape.

He will be dearly missed by all the staff at Medscape Education who have had the honor of working with him over the years.

Steering Committee Chair

Tina Vilsbøll, MD, DMSc
Head of Diabetes Research,
Gentofte Hospital,
University of Copenhagen,
Copenhagen, Denmark

Steering Committee Members

Stephen C. Bain, MD, MBBS, FRCP
Professor of Medicine (Diabetes), Institute of Life Science, Swansea University College of Medicine; Clinical Lead for Diabetes, ABMU Health Board, Swansea, United Kingdom
Alice Y.Y. Cheng, MD, FRCPC
Endocrinologist, Trillium Health Partners and St Michael's Hospital; Associate Professor, University of Toronto, Toronto, Ontario, Canada
Stephan Matthaei, MD
Professor of Medicine, Diabetes Center Quakenbrück, Hannover, Germany

Eduard Montanya, MD, PhD
Professor, Department of Clinical Sciences, University of Barcelona; Chief, Department of Diabetes, Bellvitge University Hospital, Barcelona, Spain
Richard Pratley, MD
Samuel E. Crockett, MD Chair in Diabetes Research; Director, Florida Hospital Diabetes Center; Senior Investigator, Translational Research Institute for Metabolism and Diabetes; Adjunct Professor, Sanford/Burnham Medical Research Institute, Orlando, Florida, USA

Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.

Supported by an independent educational
grant from

Downloadable Slide Kit

Advances in Modern Diabetes Management -- Tailored to Patient Needs
A slide kit emphasizing the need for optimal glycemic control in patients with type 2 diabetes

Steering Committee

Tina Vilsbøll, MD, DMSc

Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Novo Nordisk

Stephen C. Bain, MD, MBBS, FRCP

Stephen C. Bain, MD, MBBS, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cellnovo; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk

Alice Y.Y. Cheng, MD, FRCPC

Alice Y.Y. Cheng, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; SERVIER; Takeda Pharmaceuticals North America, Inc.; Valeant Pharmaceuticals International
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Valeant Pharmaceuticals International

Stephan Matthaei, MD

Stephan Matthaei, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Roche
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Omnia-Med; Roche
Received grants for clinical research from: Roche

Eduard Montanya, MD, PhD

Eduard Montanya, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk

Richard Pratley, MD

Richard Pratley, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline; Hanmi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Novo Nordisk
Received grants for clinical research from: Eli Lilly and Company; Gilead Sciences, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Other: Received honoraria from: Novo Nordisk

	With which antihyperglycemic drug class do your patients with T2DM most often experience adverse effects that require them to discontinue treatment?
		A sulfonylurea (SU)
		A thiazolidinedione (TZD)
		A meglitinide (MEG)
		A dipeptidyl peptidase-4 (DPP-4) inhibitor
		A sodium-glucose cotransporter 2 (SGLT2) inhibitor